Myeloid differentiation (MD)-2 is linked to the cell surface as a Toll-like receptor (TLR) 4-bound protein though may also function as a soluble receptor to enable the lipopolysaccharide (LPS)-driven response. We recently demonstrated the importance of MD-2 either as a cell-associated or as a soluble receptor in the control of intestinal epithelial cell response toward LPS. High levels of circulating MD-2 were recently proposed as a risk factor for infectious/ inflammatory diseases as septic shock. We hypothesized that MD-2 might be present in sera from patients with inflammatory bowel disease and have pathogenic consequences. We analysed MD-2 activity in sera from patients with inflammatory bowel disease or from healthy subjects. We measured MD-2 activity as the capacity to mediate LPS-driven stimulation of intestinal epithelial cells (HT29). We found that sera from patients with inflammatory bowel disease, particularly Crohn's disease, endowed HT29 cells with a markedly higher LPS-dependent stimulating capacity as compared to sera from healthy subjects. The effect of sera was specific for LPS activation and was reduced in the presence of anti-MD-2, and anti-TLR4 antibodies. We conclude that sera from patients with inflammatory bowel disease might contain increased MD-2. This might result in higher local availability of the protein leading to a loss of tolerance toward gut microbiota.
INTRODUCTION
Inflammatory bowel disease (IBD) is characterized by a relapsing and remitting inflammation of the gastrointestinal tract. The two most common forms of IBD are Crohn's disease and ulcerative colitis. The pathogenesis involves an inappropriate and on-going activation of the mucosal immune system driven by the presence of the intestinal microbiota in a genetically predisposed patient. Intestinal microbiota are suspected to play a role in initiating the immune system leading to characteristic inflammation. In this setting, innate immunity against commensal-associated molecular patterns such as lipopolysaccharide (LPS) may play a major pro-inflammatory role. Cell activation by LPS is recognized to be optimal in the presence of serum and requires a sequential interaction with at least four host proteins -LPS-binding protein (LBP), soluble CD14, myeloid differentiation (MD)-2, and Toll-like receptor (TLR) 4. Serum LBP facilitates the extraction of single LPS molecules from aggregates or from the bacterial wall and delivers LPS monomers to CD14. 1, 2 The LPS:CD14 complex is the preferred presentation for MD-2 to form monomeric LPS:MD-2 that activates membrane TLR4 and triggers LPS-dependent activation. [2] [3] [4] Gene deletion and LPS-binding studies demonstrated that only MD-2 and TLR4 are necessary for LPS responsiveness while LBP and CD14 only facilitate LPS binding to MD-2. [5] [6] [7] [8] Besides LBP and CD14 (long-recognized as serum constituents), recent evidence indicates that MD-2 also exists as a soluble, active, serum constituent. 9 In agreement, MD-2 is known to be secreted by cells expressing high levels of the protein.
Both cellular and secreted MD-2 mediate LPS responsiveness in human embryonic kidney HEK293 cells transfected with TLR4, which lack MD-2 and the ability to sense LPS. 4, 10, 11 Likewise, supernatants from intestinal epithelial cells (IECs) transfected with MD-2 confer LPS responsiveness to hyporesponsive IECs that express sufficient TLR4 but low MD-2.
12 MD-2 concentration in normal serum was estimated to be approximately 50 nM, 9 and may be markedly increased during the course of infectious or inflammatory diseases such as septic shock, and rheumatoid arthritis. 13 It was suggested that serum MD-2 may play an important role in the regulation of the immune/inflammatory response to bacterial pathogens. Changes in serum MD-2 may have functional consequences particularly in micro-environments rich in bacteria (such as the gut lumen), and play a crucial pathogenic role during IBD. Since IECs express low MD-2 levels (that appeared to control LPS responsiveness both in vitro and in vivo 12, 14 ) , it is reasonable to speculate that intestinal tolerance to Gram-negative bacteria may be broken as a result of IEC exposure to MD-2 leaking from extracellular sources as blood serum. Loss of tolerance to bacteria is considered as a central event in the pathogenesis of IBD, 15, 16 therefore, serum MD-2 expression might represent an important regulatory parameter that predisposes to or amplifies intestinal inflammation. MD-2 tends to polymerize and exists as a biologically active monomeric form together with a collection of covalently-aggregated multimers of different sizes that lack biological activity. 17 Therefore, to investigate the presence of functional MD-2 in serum, we developed a strategy based on the capacity of MD-2 to mediate LPS-dependent stimulation in human IECs. This was accomplished using a model of a LPS-hyporesponsive IEC (HT29) stably transfected with TLR4 or MD-2, expressing low or high levels of active MD-2, and, therefore, differentially sensing the effect of biologically active MD-2. This methodology allowed the detection of MD-2 in normal serum and appeared as a highly sensitive tool to investigate active MD-2 in health and disease. The LPS-dependent stimulation was evaluated as the release of interleukin (IL)-8 or the production of cyclooxygenase (Cox)-2 and the related release of prostaglandin (PG)E 2 , all well-known markers of intestinal inflammation. In the present study, we aimed to evaluate serum MD-2 activity in IBD patients either in flare-up or in remission, and to investigate its pathophysiological implications.
PATIENTS AND METHODS

Patients and sera samples
Blood samples (4-5 ml) were collected from 39 IBD patients during flare-up (n ¼ 21) or remission (n ¼ 18) phases. Diagnosis of IBD was defined according to clinical, radiological, endoscopic, and histological criteria. 18 Characteristics of the patients are described in Table 1 . Samples obtained within 24 h after the admission were centrifuged (400 g, 10 min, 4 C), and serum was stored at À70 C. C-reactive protein levels were measured in our clinical laboratory facilities. Controls consisting of samples from 11 healthy volunteers (8 males, 3 females; aged 34 AE 4 years) and seven patients with septic shock (4 males, 3 females; aged 51 AE 6 years) were obtained using the same protocol. Informed consent was given by every participant according to the Declaration of Helsinki.
Reagents and antibodies
Lipopolysaccharide (Escherichia coli O55:B5, protein 51%, RNA 51 %, catalogue number L4524), indomethacin, dexamethasone-21 phosphate, Bay 11-7082, IL-1b, and TNF-a were purchased from Sigma (St Louis, MO, USA). The p-38 inhibitor SB203580 was from Biomol (Plymouth, PA, USA). Mouse monoclonal anti-MD-2 (288307), goat polyclonal anti-TLR4 (AF1478 recognizing the extracellular domain), IL-8 detection ELISA (Duoset), and the kit for competitive assay-linked immunoassay (EIA) for PGE 2 detection were from R&D (Minneapolis, MN, USA). Monoclonal anti-TNF-a (Infliximab) was from Centocor (Leiden, The Netherlands). Goat polyclonal anti-LBP (K-15), rabbit polyclonal anti-CD14 (M-305), goat polyclonal anti-actin (I-19) and mouse monoclonal anti-Cox-2 (29) were from Santa Cruz (Santa Cruz, CA, USA). Horseradish-peroxidase conjugated antibodies were from Rockland (Gilbertsville, PA, USA). Blasticidin, the HA-tagged TLR4, the MD-2 expression vector (punoha-htlr4a, puno hmd-2), and the empty vector were from Cayla InvivoGen (Toulouse, France). The protease inhibitor cocktail was from Roche GmbH (Mannheim, Germany). Bicinconinic acid (BCA) protein assay reagent was from Uptima-Interchim (Montlucon, France). The ECL detection reagents were from Amersham (Buckinghamshire, UK). Dulbecco's modified Eagle's culture medium (DMEM), fetal calf serum (FCS), penicillin-streptomycin, and phosphate buffered saline (PBS) were from Invitrogen (Paisley UK).
Cell culture and transfection protocol
Intestinal epithelial cells (HT29), obtained from the European Collection of Cell Cultures (ECCC, Wiltshire, UK), were cultured in DMEM supplemented with 10% FCS, and 1% penicillin-streptomycin at 37 C in a 5% CO 2 /air atmosphere. Transfections were performed using the nucleofector kit from Amaxa GmbH (Köln, Germany), as previously described. 12 Briefly, cells (5 Â 10 5 , passages 30-40) were resuspended in 100 ml of the Amaxa nucleofector solution. Expression plasmids (5 mg empty vector, TLR4-HA, MD-2) were mixed with the cell suspension, transferred into Amaxa certified cuvettes, and electroporated according to the manufacturer's instructions. Cells were resuspended in complete culture medium and seeded in 24-well plates. To obtain stable clones, the selection agent blasticidin (30 mg/ml) was added for 10 days. Resistant clones were isolated using glass cylinders and tested for LPS stimulation. Selected clones were further cultured in 10 mg/ ml blasticidin. Transfection efficiency monitored by microscopic fluorescence using anti-MD-2 and anti-TLR4 antibodies appeared 460%.
Myeloid differentiation-2 activity assay MD-2 activity was evaluated as the capacity of IECs to increase IL-8, Cox-2 or PGE 2 production in response to LPS. Though indirect, this methodology to evaluate MD-2 activity was previously validated using TLR4-transfected HEK293 and allowed evaluation of biologically active MD-2 in sera from patients with septic shock. 13 Control HT29 IECs (stably transfected with the empty vector), or cells stably transfected with either TLR4 (HT29-TLR4) or MD-2 (HT29-MD-2) were used. Cells were seeded in 6-24-well culture plates and cultured in complete DMEM until nearly confluent. Initial experiments were performed using various serum concentrations (5, 10 or 20%) to determine the optimal response to LPS. This response increased in a dose-dependent manner and was maximal for 20%. Therefore, 20% serum was used in subsequent experiments. Cells were left untreated or stimulated with 100 ng/ml LPS for 24 h. Supernatants were collected and stored at À70 C until IL-8 or PGE 2 determination. Cells were lysed in ice-cold PBS buffer containing 1% Triton X-100; and the protease inhibitor cocktail, and stored at À70 C until Cox-2 determination. In some experiments, cells were stimulated with IL-1b (25 ng/ml) or TNF-a (10 ng/ml). In blocking experiments, cells were incubated with anti-MD-2 (2 or 20 mg/ml), anti-TLR4 (10 mg/ ml), anti-LBP (10 mg/ml), or anti-CD14 (10 mg/ml) for 1 h before LPS stimulation. Control experiments were carried out using the corresponding IgG isotypes. In other experiments, the anti-inflammatory steroid dexamethasone (10 mM), the Cox-2 inhibitor indomethacin (10 mM), the p-38 inhibitor SB203580 (20 mM), the NF-kB inhibitor Bay 11-7082 (20 mM), or the anti-TNF-a monoclonal antibody Infliximab (10 mg/ ml), were added to the incubation medium 1 h before LPS stimulation. In experiments designed to investigate whether the stimulating capacity of serum required interaction with either the apical or the basolateral pole of IECs, we used a special subset of IECs, HT29 5M12, that spontaneously polarize. To allow separate access of serum to the apical or the basolateral pole of IECs, cells were plated on 6-well culture-treated polycarbonate Transwell filters (24 mm diameter, 0.4 mm pore size; Costar, Corning, NY, USA) at a density of 100 Â 10 3 cells/filter, and grown for 15 days until confluence. Stimulations were performed either on the apical (upper chamber) or the basolateral (lower chamber) side of the cell layer.
Assay of interleukin-8 and prostaglandin E 2
Levels of IL-8 and PGE 2 released by HT29 were determined in aliquots of the culture medium by means of commercially available ELISA and EIA kits, respectively, according to the instructions of the manufacturer. Data were normalized by the protein content determined in the corresponding cell lysates using the BCA protein assay with bovine serum albumin as standard.
Western blot
Western blot analysis was performed to examine the expression of Cox-2 in cell lysates. For these experiments, cells were plated in 6-well culture plates and stimulated, or not, with LPS in the presence of sera from healthy subjects or patients with active Crohn's disease. Equivalent amounts of protein lysates (25 mg) were loaded on 7.5% acrylamide gels, and subjected to electrophoresis. Primary antibodies, anti-Cox-2, and anti-actin were diluted to 1/100 and 1/500, respectively. Horseradish-peroxidase-conjugated secondary antibodies were diluted to 1/10,000. Immunoreactivity was visualized using ECL reagents.
Statistical analysis
Data are expressed as mean AE SEM and comparisons between two groups were performed using a non-parametric Mann-Whitney U-test. The level of significance was set at P50.05. Correlation between sera MD-2 activity and C-reactive protein was analysed using the Spearman's correlation. Statistical analysis was performed using GraphPad Prism v.3.0.
RESULTS
Sera from IBD patients enhance LPS-induced IL-8 secretion
Experiments performed with HT29 control Stimulation with LPS in the presence of sera from patients with active Crohn's disease led to significantly higher values IL-8 secretion (4.8 AE 1.01 ng IL-8/mg protein) as compared to sera from healthy controls (1.1 AE 0.08 ng IL-8/mg protein; P50.001; Fig. 1A ).
No significant differences between healthy subjects and patients with Crohn's disease were observed in the absence of LPS.
Experiments performed with HT29-TLR4
The response observed was comparable to that observed in control HT29 but with a higher magnitude (Fig. 1B) . Lipopolysaccharide-induced values of IL-8 were significantly increased with sera from active Crohn's disease patients, as compared to healthy controls (28.6 AE 9.2 vs 2.6 AE 0.23 ng IL-8/mg protein, respectively; P50.05). Sera from patients with active ulcerative colitis also led to higher LPS stimulation than controls (8.9 AE 1.6 vs 2.6 AE 0.23 ng IL-8/mg protein, respectively; P50.05). However, the IL-8-induced secretion by TLR4-expressing HT29 cells was lower in response to sera from ulcerative colitis than Crohn's disease patients (8.9 AE 1.6 vs 28.6 AE 9.2 ng IL-8/mg protein, respectively; P50.05; Fig. 1B) . Data from IBD patients in remission are also depicted in Figure  1B . Values observed with Crohn's disease or ulcerative colitis patients in remission remained significantly higher than those observed with healthy controls though they were decreased as compared to the active disease: 4.2 AE 0.8 (Crohn's disease), and 5.0 AE 1.1 (ulcerative colitis) vs 2.6 AE 0.23 (healthy controls) ng IL-8/mg protein (P50.05). Though we did not find a significant correlation between MD-2 levels and the location of the disease, collectively, in all IBD patients, these levels significantly correlated with the level of C-reactive protein (r ¼ 0.79; P50.001).
Experiments performed with HT29-MD-2
As expected, LPS stimulation of HT29-MD-2, in the presence of sera from patients and controls, led to markedly higher values of IL-8 secretion as compared to HT29 control or HT29-TLR4. In these cells, however, no significant differences between groups were observed (Fig. 1C) .
Comparison with sera from patients with septic shock
The activity of MD-2 was compared between Crohn's disease patients and patients with septic shock at different serum concentration since low concentrations (5-10%) are known to contain optimal MD-2 activity in septic patients. Sera MD-2 activity in septic shock was higher as compared to sera from active Crohn's disease patients and was maximal for 10% concentration (42.3 AE 20.8 vs 5.3 AE 1.2 ng IL-8/mg protein, respectively; P50.001). Unlike Crohn's disease patients, and as expected, serum from patients with septic shock was most efficient at lower concentrations (5-10%). These dose-response experiments are illustrated in Figure 1D .
The enhancing effect of sera from patients with Crohn's disease is specific for LPS activation likely via MD-2
To address the specificity of the observed LPS-enhancing effect of sera from Crohn's disease patients, we tested its effect on IEC responsiveness to pro-inflammatory cytokines such as TNF-a and IL-1b. Results are given in Figure 2 . Both cytokines induced a stimulating effect that was not significantly affected by the presence of either healthy or Crohn's disease sera. This indicated that the increased LPS-driven responsiveness observed with sera from patients with Crohn's disease is not a general phenomenon but specific for the interaction of LPS with MD-2. Similar data were observed in HT29 control cells (only data with HT29-TLR4 are shown in Fig. 2) .
To clarify further whether the stimulating effect of sera was mediated by MD-2, we next analysed the effect of sera from active Crohn's disease patients in the presence of neutralizing antibodies, anti-MD-2, and anti-TLR4 (2, 20 mg/ml and 10 mg/ml final concentration, respectively). Additional experiments were performed with anti-LBP (10 mg/ml) and anti-CD14 (10 mg/ ml) alone or combined with anti-MD-2. As illustrated in Figure 3 (upper panel) these antibodies had negligible effect in unstimulated cells. However, in LPS-stimulated cells, a significant inhibitory effect was observed in the presence of anti-MD-2 (P50.05 vs LPS alone), anti-TLR4 (P50.01 vs LPS alone), anti-LBP, and anti-CD14 (P50.05 vs LPS alone; Fig. 3 , lower panel). Though incomplete, the blocking effect of anti-MD-2 was dose-dependent and was higher for 20 mg/ml (54% inhibition). In addition, a synergetic blocking effect was observed when anti-MD-2 was added in combination with anti-LBP or anti-CD14 (P50.001 vs LPS alone; Fig. 3, lower panel) . No blocking effect was observed with these antibodies in cells stimulated with healthy sera or stimulated with either IL-1b or TNF-a (data not shown). We next investigated the effect of pharmacological inhibitors of two essential targets of the LPS-mediated TLR4/MD-2 signaling pathway in order to link the stimulating effect of Crohn's disease sera to underlying signaling events.
Results from these experiments are depicted in Figure 4 . Bay 11-7082 (a NF-kB inhibitor) and SB2035820 (a p38 inhibitor) significantly inhibited the release of IL-8 by HT29-TLR4 cells. Both basal (upper panel) and LPS-stimulated (lower panel) secretion of IL-8 was affected (P50.001 vs untreated cells). The effect of Infliximab was investigated in order to estimate whether some IL-8 secretion measured in IECs might be attributable to stimulation by TNF-a over-expressed in sera from IBD patients. These experiments revealed no inhibition of IL-8 secretion by Infliximab in cells incubated with sera from active Crohn's disease patients (Fig. 4) . However, the strong inhibitory capacity of Infliximab observed in experiments with added TNF-a attested to the potent activity and therapeutic value of this antibody (Fig. 4, lower panel) .
Serum from patients with Crohn's disease enhances LPS-induced Cox-2 expression and PGE2 secretion
We next investigated whether the putative MD-2 activity observed in active Crohn's disease sera could also affect the stimulating effect of LPS on Cox-2 expression and activity. Western blot analysis of cell lysates prepared from HT29-TLR4, stimulated or not with LPS in the presence of sera from healthy controls or patients with active Crohn's disease, are shown in Figure  5 . Cell exposure to sera from patients with active Crohn's disease, but not healthy sera, allowed LPS to induce Cox-2 expression (Fig. 5A ). This stimulating effect was not affected by dexamethasone, indomethacin, or Infliximab (Fig. 5B) . As observed for IL-8 secretion, TNF-a-induced Cox-2 expression was clearly blocked by Infliximab (Fig. 5B) .
As depicted in Figure 6 , sera from healthy controls were unable to support the LPS-induced PGE 2 secretion. However, sera from patients with active Crohn's disease significantly increased this capacity (P50.05) in HT29-TLR4 cells (Fig. 6, upper panel) . This stimulating capacity of sera from active Crohn's disease patients was also observed, though to a lesser extent, in HT29 control cells but not in MD-2 expressing HT29 cells (data not shown). In keeping with data on Cox-2 expression, the LPS-stimulated PGE 2 secretion was unaffected by dexamethasone, or by Infliximab, while the effect of added TNF-a was markedly blocked by Infliximab. As expected, sera-enhanced, LPS-driven, PGE 2 secretion was significantly reduced by the inhibitor of Cox-2 activity, indomethacin (Fig. 6 , lower panel).
Enhancing effect of sera from patients with Crohn's disease in polarized cells
The apical versus basolateral LPS-stimulating effect of sera from patients with active Crohn's disease was tested in polarized IECs grown to confluence on Transwell filters. As depicted in Figure 7 , IL-8 secretion was predominantly basolateral. Though activation was observed at the basolateral pole, maximal activation was observed at the apical pole. Thus, our data confirm the capacity of sera from Crohn's disease patients to confer LPS responsiveness at the luminal side of IECs, where bacteria should be. 
DISCUSSION
Sera from patients with IBD, and especially Crohn's disease, were markedly more potent than sera from healthy subjects in supporting LPS activation of hyporesponsive IECs. This effect appeared specific for LPS activation, and did not affect the stimulating effect of pro-inflammatory cytokines (IL-1b, TNF-a). In addition, the stimulating effect of sera from patients with Crohn's disease was sensitive to the endogenous cell expression of TLR4, MD-2, and to the neutralizing effects of antibodies raised against both proteins. Of note, the neutralizing effect of anti-MD-2 markedly synergized when combined with anti-LBP and anti-CD14 antibodies. Though blood serum contains numerous factors that may affect the inflammation state, our data suggest that sera from patients with IBD, and particularly Crohn's disease, whether in active or remission phase, contain increased levels of soluble biologically active MD-2.
Comparisons between active Crohn's disease and ulcerative colitis patients suggested a significantly higher MD-2 activity in Crohn's disease patients. Though this MD-2 activity remained elevated in remission patients, comparison between Crohn's disease patients, either in active or remission periods, revealed significantly lower MD-2 activity in remission patients. These differences contrast with previous data on TLR4 expression that was found similarly increased in patients with Crohn's disease and ulcerative colitis regardless of whether assessed in active or remission state. 19 Therefore, we suggest that sera MD-2 levels in IBD more closely reflect the activity of the disease. Comparisons between Crohn's disease and septic shock patients revealed a markedly higher MD-2 activity in septic shock. In agreement, a potent circulating MD-2 activity was recently reported in septic patients using a similar methodological approach. 13 The activating effect of sera in IECs appeared totally resistant to the steroid dexamethasone. The beneficial effects of steroids observed in IBD likely do not derive from a direct effect of the drug on the intestinal epithelia but from anti-inflammatory effects on circulating cells or on cells of the inflammatory infiltrate lining the intestine layer, namely monocytes/macrophages. Consistent with this hypothesis is the finding that steroid resistance in patients with Crohn's disease is associated with activation of epithelial cells, rather than lamina propria macrophages. 20 The stimulating capacity of sera from active Crohn's disease appeared to depend on the classical LPS-mediated TLR4/MD-2 signaling pathway, since it was significantly decreased by pharmacological inhibitors of both NF-kB and p38 activities. Low-to-negligible inhibition of the stimulating effect of IBD sera was observed with the anti-TNF-a antibody, Infliximab. In some patients (1 from 6), this finding may be attributable to stable therapy with Infliximab. An alternative explanation relies on values of TNF-a concentrations determined in sera from patients with IBD. 21 Though higher TNF-a levels were observed in sera from IBD patients as compared to healthy donors, these concentrations appeared below levels known to stimulate IEC in vitro (40.01 ng/ml). However, IECs might be exposed to higher concentrations of TNF-a leaking from serum and secreted by neighbouring macrophages. Beneficial effects of Infliximab might target this micro-environment.
We previously demonstrated that human IECs express low amounts of MD-2 and barely respond to LPS stimulation even though they normally express TLR4. Responsiveness to LPS in these cells could be only conferred by transfection of MD-2 or by addition of soluble MD-2 to the incubation medium. 12 Similar data were demonstrated in other epithelia such as lung human epithelial cells, 22 and conjunctival epithelial cells. 23 This is consistent with a model in which tissue epithelial cells express functional levels of TLR4 but inadequate MD-2 and, therefore, remain resistant to LPS unless MD-2 is brought by either neighbouring cells or by sera exudates. Indeed, soluble MD-2 has been detected in both oedema fluids and urine of patients with septic shock, 13 resulting from leakage of MD-2 from blood proteins. Increased permeability with ulcerations present in IBD are obvious additional sources that may intensify this movement. The cellular source for circulating MD-2 is not the monocyte lineage, and has remained so far elusive. A recent study suggests that MD-2 is an acute phase protein secreted by hepatocytes and up-regulated by IL-6 after the induction of the acute phase response. 24 From our experiments performed in polarized cells, we can speculate that MD-2 as an acute phase protein might activate gut epithelial response to LPS either via the systemic route at the basolateral pole or reach the intestinal lumen to activate the apical pole response. In agreement, exacerbations of IBD secondary to superimposed infections, whether gastrointestinal or not, are known to precipitate flare-up in IBD. 25, 26 This could be related to variations in MD-2 that contribute to IBD relapse in predisposed individuals.
We also demonstrated that sera from IBD patients allowed LPS to induce Cox-2 expression and PGE 2 secretion. As inflammation has been shown to be a risk factor of progression to colorectal cancer in ulcerative colitis, 27 it can be hypothesized that permanent exposure to MD-2 can lead to increased Cox-2 and PGE 2 in colonic epithelial cells and, thereby, favour transition from inflammation to cancer. Further studies on the role of MD-2 in cell proliferation and/or cell transformation represent, therefore, a promising track.
CONCLUSIONS
The data suggest increased concentrations of biologically-active, circulating MD-2 in IBD. This might result in higher local availability of MD-2 and, thereby, could lead to loss of tolerance toward gut microbiota. We suggest that circulating MD-2 is a crucial factor in the initial step leading to loss of tolerance to gut microbiota, Gram-negative bacteria, and IBD. Our data suggest that MD-2 is a major candidate in regulating the intestinal response to bacteria by interacting with LPS and transmembrane TLR4.
